Efficacy of A/H1N1/2009 split inactivated influenza A vaccine (GC1115) in mice and ferrets
- 15 Downloads
To evaluate the efficacy of a non-adjuvant A/H1N1/2009 influenza A vaccine (GC1115), we demonstrated the immunogenicity and protective efficacy of GC1115 in mouse and ferret models. The immunogenicity of GC1115 was confirmed after intramuscular administration of 1.875, 3.75, 7.5, and 15 μg hemagglutinin antigen (HA) in mice and 7.5, 15, and 30 μg HA in ferrets at 3-week intervals. A single immunization with GC1115 at HA doses > 7.5 μg induced detectable seroconversion in most mice, and all mice given a second dose exhibited high antibody responses in a dose-dependent manner. The mice in the mock (PBS) and 1.875 μg HA immunized groups succumbed by 13 days following A/California/ 04/09 infection, while all mice in groups given more than 3.75 μg HA were protected from lethal challenge with the A/California/04/09 virus. In ferrets, although immunization with even a single dose of 15 or 30 μg of HA induced detectable HI antibodies, all ferrets given two doses of vaccine seroconverted and exhibited HI titers greater than 80 units. Following challenge with A/California/04/09, the mock (PBS) immunized ferrets showed influenza-like clinical symptoms, such as increased numbers of coughs, elevated body temperature, and body weight loss, for 7 days, while GC1115- immunized ferrets showed attenuated clinical symptoms only for short time period (3–4 days). Further, GC1115-immunized ferrets displayed significantly lower viral titers in the upper respiratory tract (nasal cavity) than the mock vaccinated group in a dose-dependent manner. Taken together, this study demonstrates the immunogenicity and protective efficacy of GC1115 as a non-adjuvanted vaccine.
KeywordsH1N1 pandemic influenza vaccination immunogenicity protective efficacy
Unable to display preview. Download preview PDF.
- Cheong, H.J., Song, J.Y., Heo, J.Y., Noh, J.Y., Choi, W.S., Park, D.W., Wie, S.H., and Kim, W.J. 2011. Immunogenicity and safety of influenza A/H1N1 2009 inactivated split-virus vaccine in young and older adults: MF59 adjuvanted vaccine versus nonadjuvanted vaccine. Clin. Vaccine Immunol. 18, 1358–1364.CrossRefGoogle Scholar
- Dawood, F.S., Iuliano, A.D., Reed, C., Meltzer, M.I., Shay, D.K., Cheng, P.Y., Bandaranayake, D., Breiman, R.F., Brooks, W.A., and Buchy, P. 2012. Estimated global mortality associated with the first 12 months of 2009 pandemic influenza A H1N1 virus circulation: a modelling study. Lancet Infect. Dis. 12, 687–695.CrossRefGoogle Scholar
- Katz, J., Hancock, K., Veguilla, V., Zhong, W., Lu, X., Sun, H., Butler, E., Dong, L., Liu, F., and Li, Z. 2009. Serum cross-reactive antibody response to a novel influenza A (H1N1) virus after vaccination with seasonal influenza vaccine. MMWR Morb. Mortal. Wkly. Rep. 58, 521–524.Google Scholar
- Kendal, A.P., Skehel, J.J., Pereira, M.S., and WHO Collaborating Centers for Reference and Research on Influenza. 1982. Concepts and procedures for laboratory-based influenza surveillance. World Health Organization, Geneva, Switzerland.Google Scholar
- Louten, J. 2016. Essential human virology. Academic Press.Google Scholar
- Lu, X., Tumpey, T.M., Morken, T., Zaki, S.R., Cox, N.J., and Katz, J.M. 1999. A mouse model for the evaluation of pathogenesis and immunity to influenza A (H5N1) viruses isolated from humans. J. Virol. 73, 5903–5911.Google Scholar
- Munster, V.J., de Wit, E., van den Brand, J.M., Herfst, S., Schrauwen, E.J., Bestebroer, T.M., van de Vijver, D., Boucher, C.A., Koopmans, M., and Rimmelzwaan, G.F. 2009. Pathogenesis and transmission of swine-origin 2009 A (H1N1) influenza virus in ferrets. Science 325, 481–483.CrossRefGoogle Scholar
- Schild, G., Wood, J., and Newman, R. 1975. A single-radial-immunodiffusion technique for the assay of influenza haemagglutinin antigen: Proposals for an assay method for the haemagglutinin content of influenza vaccines. Bull. World Health Org. 52, 223.Google Scholar